Gabor ..Now there you go again with your math and logic ...we really need to talk about that :>)
Basically agree , except I'm not as confident as you that RI will be stopped at interim or that you'll see the end users you envision , unless Vascepa costs the consumer not much more ( and preferably less ) then the closest DS alternative ( Omegia Via EPA at about %62 a month.
I do not agree with your numbers, and I would like to see citations backing them up. I am unaware that statins directly interfere with EPA as you claim. This effect may have slipped my attention, and I would be very grateful if you could provide me with a source. I am aware of the fact statins facilitate the conversion of ALA into AA. Most of my reading suggest that statins and EPA have a synergistic relationship.
Which I re post here. Unless you have a source that refutes this then I am going to accept it. This says the AA levels in the USA are 60% higher than those in Japan.
What this means is your statement, "the average EPA levels in Japan is 3 times higher than in America", is likely incorrect.
You apparently do not understand my statement.."if we just equalize the EPA levels we get AA/EPA ratio of 1.6 to 1". This is a hypothetical statement regarding the math and is correct. The actual R-IT numbers are going to be different.
Yes there are some differences between JELIS and REDUCE-IT. The ones you mention are IMHO not that important. The most significant is the difference in relative CVD risk between the two groups. This reflecting the difference in diet.
News 
Market Data 
Discover 
